MyoKardia appoints physician, executive David Meeker to board of directors
MyoKardia named pharmaceutical executive and physician David Meeker, MD, to its board of directors on April 18.
Meeker is the executive vice president and head of Sanofi Genzyme, the company’s specialty care global business unit that focuses on rare diseases, multiple sclerosis, oncology and immunology. He was previously Genzyme’s CEO and president and the director of the Cleveland Clinic’s pulmonary critical care fellowship.
MyoKardia, based in San Francisco, is developing precision medicines to treat serious and rare cardiovascular diseases. The company is focusing on treating heritable cardiomyopathies, including hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy.
The company’s most advanced product, known as MYK-461, is currently being evaluated in a phase 2 study of patients with symptomatic, obstructive HCM. The FDA has granted MYK-461 an orphan drug designation for that subset of patients.
In 2014, MyoKardia helped form the Sarcomeric human cardiomyopathy registry that includes data on 10,000 individuals with heritable cardiomyopathies.
In March, MyoKardia appointed Genomic Health CEO Kim Popovits and former Merck chief marketing officer and senior vice president of human resources Wendy Yarno to its board of directors.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.